PharmAbcine Inc.
We strive to become a leading biotech company that contributes to human health and well-being by providing innovative therapeutic antibodies to patients with unmet medical needs. We have been committed to developing novel antibody therapeutics since the company was founded in 2008 and was successfully listed on KOSDAQ in 2018. Our goal is to focus on the development of novel antibody therapeutics and become a leading biotech company that contributes to human health and well-being.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
About us
PharmAbcine is a clinical-stage biotech company focusing on the development of fully human antibody therapeutics to treat neovascular disorders, tumors, and other medically unmet diseases. It provides therapeutic antibodies for a wide spectrum of indications from oncology, immuno-oncology, ophthalmology, pulmonology, to renal pathology.
PharmAbcine has its own HuPhage library and innovative selection system. PharmAbcine's advanced 3G expression system accommodates high levels of antibody production and steady reproducibility. With these cutting-edge technology platforms, it provides state-of-the art antibody generation services.
PharmAbcine also has unique knowhow in the area of the antibody production, early drug development, and clinical development.